play response data. Analysis by question, category and demographic descriptor was performed. RESULTS: Nine of learners were consented and completed a pre-study assessment within 4 weeks. Learners reported a notable increase in improving animal health and production as a result of the training. Most learners (>90%) view the program as a worthwhile investment in their career. Significantly less managers feel the same (28%) and this may be related to the higher cost of the program. The highest job impact for the training is 1.7 times the top 25% benchmark. Surprisingly, those with greater than 10 years tenure find the program to be just as worthwhile or more compared to the other tenure groups and the largest group with the longest tenure saw the greatest job impact from the training. CONCLUSIONS: The training provides much needed resources for the industry since most learners found it a worthwhile investment and the ROI calculation is high. This analysis allows for data driven decisions to be made for program adjustment and learner selection.

PIH44

TRENDS IN PATIENT CENTERED RESEARCH IN THE PUBLISHED LITERATURE

Crosby NA, Veley KM, Williams H1,2

1PPD, Wilmington, NC, USA; 2PPD, Morrisville, NC, USA; 3PMG Research Inc., Wilmington, NC, USA

OBJECTIVES: In a previous study we found a steep increase in the use of the term “patient-centered” in the published literature from <1 articles in the 1960s to >3000 in the 2010s. We also noted an increase in the proportion of articles in each decade reporting original research (17 vs 90%). The objective of this study was to further examine the subset of articles reporting original research. METHODS: We searched EMBASE for articles written in English between 1950-2013 with ‘patient-centered’ in the title or abstract. We selected a random sample of 10 articles within each decade and coded data from the title and abstract on the focus of the article (healthcare research, or teaching). We selected those focused on research and extracted additional data on the study design, data collection methods, number of cases, comparator group, type of data analysis, results, and main conclusions of the study. RESULTS: Of 2222 reported original research, from 1966-2013. Articles in earlier decades tended to focus on research (75%), whereas articles published more recently used more sophisticated study designs (>75%). The majority of studies in all decades employed descriptive statistics, however multivariate methods were used in 25% of studies in the 2010s. The use of a comparator group (16 vs 50%) and the average number of subjects (38 vs 667) also increased steadily over time. CONCLUSIONS: In addition to the increase in original research publications with “patient-centered” in the title or abstract over the last 50 years, we observed an increase in scientific and methodological rigor among these original research articles. These findings are consistent with the rise in personalized-medicine in the healthcare industry today, as well as the upsurge in the use of patient-reported outcome data that characterizes clinical research today.

PIH45

CAN A WEB-BASED TOOL TO FACILITATE COMMUNICATION BETWEEN PATIENT AND HEALTHCARE PROVIDERS IMPROVE PATIENT-REPORTED OUTCOMES?

Clevenger D

Personal Healthcare Information, Pittstown, NJ, USA

OBJECTIVES: Patients with barriers such as normal anxiety around illness, low assurance and decision making may have trouble communicating with their healthcare providers (HCP). HCPs are under increasing pressure to see more patients daily. Can a web-based training and worksheet help patients have improved outcomes, even in patients with barriers to communication? METHODS: In partnership with FCA, Optum, Optum developed an electronic, printable worksheet that contained the following: a detailed description of their primary complaint, including location, duration, and intensity of symptoms; a therapy preferences statement and a statement of symptom management goals. RESULTS: Of 25 patients, 14 responded to an outcomes survey: 10/14 (71%) of the respondents were female, with a range of 50-72 years of age 6/14 (42.9%) consulted 5 or more HCPs and 9/14 (64.3%) had 5 or more healthcare visits. They had some miscommunication with their HCP regarding medication. For their healthcare issue prior to completing the worksheet 9/14 (64.3%) indicated they had some miscommunication with their HCP regarding medication. A majority of patients had received costly blood tests (81.8%), X-rays (72.7%), and MRU/CATS scans (63.6%) for their healthcare issue. Most patients (78.6%) used the worksheet to have a discussion around a new treatment option they hadn’t previously discussed, and almost half (61.4% (42.9%)) were able to get a diagnosis for a healthcare issue not previously diagnosed using the worksheet. Many 9/14 (64.3%) said the worksheet helped reduce office visit related anxiety and helped them discuss symptom management goals. CONCLUSIONS: This simple web-based tool was useful in facilitating communication between patients and their HCPs, which led to diagnoses, receiving new treatments, and better symptom management, even in patients with long-standing healthcare issues, multiple visits, extensive testing, and multiple healthcare providers.

PIH46

PATIENT REPORTED OUTCOMES: ARE THEY RELEVANT TO U.S. PAYERS?

Blevins M, Hughes TE2

1Optum, Lincoln, RI, USA; 2Optum, Scottsdale, RI, USA

OBJECTIVES: Identify the current and future relevance of Patient Reported Outcomes (PROs) among U.S. payers making patient access decisions for pharmaceuticals. METHODS: Double blind, semi-structured telephone interviews with 12 U.S. payers, including: National and regional commercial payers, Accountable Care Organizations, Brunswicks, Community Benefit Management, National payers, Veterans Affairs; and Department of Defense. Interviews included open-ended questioning and structured rating scales where 10=highest and 1=lowest possible score per concept. RESULTS: Payers perceive PROs as the, “Consequences of the disease and drug as assessed by the patient.” Average rating scale responses were

How relevant are PROs today? 3.7 in 5 years? 6.4 Would you like to see more PROs today? 6.1 in 5 years? 6.6 Should pharmaceutical companies invest more in PROs today? 5.6 in 5 years? 6.3 The sum of the 6 scales (min= 6, max = 60) ranged from 12 to 58, highlighting diversity across payers. PFO relevance was associated with the duration of enrollment and thus total amount of risk. DOd and ACO reports the highest relevance. In general Commercial Health plans the lowest. Education was consistently identified as a need to aid interpretation of PRO data to support patient access decisions. CONCLUSIONS: Payers’ reliance on PRO data will increase in the next five years, especially in symptomatic conditions with high objective measures of success. PRO evidence is valued as a unique predictor of clinical and economic outcomes and as a key element of performance and quality ratings. Respondents showed interest in pharmaceutical companies’ increasing use of PROs in clinical trials, creation of real world evidence and supporting PRO education.

PIH47

FOR TWO COMPANIES THE FDA PRO GUIDANCE LEADS TO SIMILAR BUT DIFFERENT MEASURES: A CASE STUDY IN PSORIASIS

Mordin N1, Brown TM2, McLeod L2, Demuro C2, Gnanasakthy A2

1RTI Health Solutions, Ann Arbor, MI, USA; 2RTI Health Solutions, Research Triangle Park, NC, USA

OBJECTIVES: The objective of this research is to evaluate whether the 2009 FDA PRO Guidance leads to development of similar measures when followed by different researchers in the same disease. Psoriasis was selected as a case study, because two companies recently published patient-reported outcome measures to assess the severity of psoriasis-related symptoms: the Psoriasis Symptom Inventory (PSI) and the Psoriasis Symptom Diary (PSD). METHODS: Full-length publications related to the development of the PSI and PSD were reviewed. Input from subject-matter experts regarding the development process and key aspects pertinent to the PRO Guidance were extracted and compared: patient population, development steps (literature review, item generation, item selection, pilot testing, item testing, item scoring), content of final measure, recall period, response options, and scoring. The authors conducted a qualitative evaluation of the differences between the measures. RESULTS: The measures were based on the literature and had similar psychometric properties. Both measures have a 24-hour recall period. However, the measures consist of different numbers of disease-specific symptoms (PSI = 8; PSD = 6). The PSI consists of 16 items (bother of symptoms = 8, severity of symptoms = 6, skin color = 1, hiding skin = 1). Additionally, the measures assess symptoms differently. The PSI uses a 5-point Likert scale, while the PSD uses an 11-point numeric rating scale; both measures equate higher scores with greater severity. CONCLUSIONS: This example demonstrates that when different experts develop patient-reported outcome measures to assess similar concepts and to align with the FDA PRO Guidance, the result is similar but not identical.

PIH48

SWITCHING IN PART D PROVISIONAL PLAN: PLAN SWITCHING VERSUS BRAND NAME DRUG SWITCHING

Ngo A

Brightspot & White Health, Temple, TX, USA

OBJECTIVES: There is a dearth of evidence on factors influencing prescription plan switching versus switching from brand name drug to generic one. However, either of this decision is associated with impact costs for patients and payers. OBJECTIVE: This study sought to identify factors and compare impact costs associated with plan switching versus switching to a non-originated drug. METHODS: The study population included Medicare Part D (stand-alone), HMO, fee-for-service or Advantage plans. The study sample included 1298 individuals responded both years surveys. Random inter- cept multinomial logistic regression models was estimated. RESULTS: Only 5% of Medicare members switched into different prescription plans in both 2007 and 2009, while about 24% individuals switched from brand name drugs to generic product to save prescription drug costs. An outcome variable of interest includes 4 categories: switched into different part D plan, switch from brand to generic drug, thought about switching but did not actually switch and didn’t do anything. The main covariates of interest include individual and plan level characteristics. Compared to “didn’t do anything” individuals were more likely to switch to different prescription plan (13%) or switched to generic drug from brand name (25%) if they were using higher number of prescription medications (p<0.04). Individuals having plans with good customer service was 54% less likely to switch into different part D plan. Compared to “didn’t do anything” individuals were 123% more likely to stay on the same plan being satisfied with the current plan if they experience “inertia” in the plan choice decision. CONCLUSIONS: Unobserved plan level characteristics matter in Part D plan switching or drug switching decisions. Consumer inertia and plan’s customer service quality appear to be important factors influencing these switching decisions.

PIH49

A CONCEPTUAL FRAMEWORK FOR TRANSLATING PATIENT-REPORTED OUTCOMES FOR IMPLEMENTATION IN CLINICAL PRACTICE AND QUALITY IMPROVEMENT EFFORTS

Isewani G, Gaur P, Gannan N, Mitchell K

Avante Health, Washington, DC, USA

OBJECTIVES: As healthcare becomes more patient-centered, patient-reported outcomes (PROs) are increasingly being used in clinical decision making. The Institute of Medicine has identified the need to develop a conceptual framework for the definition, implementing and translating PROs into valid, reliable measures of performance. METHODS: Conducted a structured literature review to identify influences in the translation of PROs, issues that impact translation, and relationships between key variables. RESULTS: Various